Warning letter
Actavis Totowa, LLC: warning letter of Feb 1, 2007
FDA warning letter UCM076260 · New Jersey District Office
Key facts
| Reference number | UCM076260 |
|---|---|
| Company | Actavis Totowa, LLC |
| Subject | CGMP/Deviations/Adulterated |
| Issue date | Feb 1, 2007 |
| Posted date | Feb 1, 2007 |
| Issuing office | New Jersey District Office |
| Product type | Drugs |
| CFR sections cited | 211.63, 211.67, 211.110, 211.111, 211.192, 211.22(a), 211.22(d), 211.67(b), 211.68(b), 211.160(b), 211.186(b)(9), 211.188(b)(10) and 1 more |
| Country | 3 |
| Inspection city | Little Falls |
| Inspection ZIP | 07424-5608 |
| Inspection start date | Jul 10, 2006 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: